HOME >> MEDICINE >> NEWS
Preclinical results of Geovax's AIDS vaccines demonstrate potential to protect against disease

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome ("AIDS") in non-human primates. The data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines.

In this trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax's DNA/MVA vaccines. Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later "controlled" (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date. Vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

"The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS," said Don Hildebrand, CEO of GeoVax Labs. "Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines."

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus' progressive and de
'"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
Financial Relations Board
6-Feb-2007


Page: 1 2

Related medicine news :

1. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
2. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
3. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
4. Targeted, oral agent Enzastaurin shows favorable results
5. Childhood obesity intervention shows promising results
6. Alpharma presents positive pharmacokinetic study results
7. UCSF brain tumor vaccine trial shows promising results
8. The eyes have it -- Autism research yields surprising results
9. ACP: Residency match results for internal medicine underscore need to redesign primary care
10. Positive results more likely from industry-funded breast cancer trials
11. Leading advocates express support for microbicide research, despite disappointing trial results

Post Your Comments:
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... 2015 Early surgery may not be ... AC joint injuries, according to new research from Tripler ... American Orthopaedic Society for Sports Medicine’s ( AOSSM ) ... when surgery was not performed. , The final study ... treatment and 17 receiving non-surgical therapy. Of the non-surgery ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Andrew Hawley of ... 1960's Who psychedelic concert posters. The Who and the Doors ... on August 2, 1968. According to Hawley, “The Who toured ... concert halls and college campuses. Perhaps the most famous Who ... Jim Morrison and the Doors on August 2, 1968 at ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
Cached News: